Nom du produit:tert-butyl N-[1-(6-bromo-3-chloroquinolin-4-yl)piperidin-4-yl]carbamate
IUPAC Name:tert-butyl N-[1-(6-bromo-3-chloroquinolin-4-yl)piperidin-4-yl]carbamate
- CAS:2172875-14-6
- Formule moléculaire:C19H23BrClN3O2
- Pureté:95%+
- Numéro de catalogue:CM1075011
- Poids moléculaire:440.77
Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:2172875-14-6
- Formule moléculaire:C19H23BrClN3O2
- Point de fusion:-
- Code SMILES:CC(C)(C)OC(=O)NC1CCN(CC1)C1=C2C=C(Br)C=CC2=NC=C1Cl
- Densité:
- Numéro de catalogue:CM1075011
- Poids moléculaire:440.77
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Quinolines
- Quinolines are an important class of biologically active heterocyclic compounds, and their derivatives usually exhibit a variety of biological activities. They can be used as antimalarial drugs and in the preparation of other antimalarial drugs. Other important activities of quinoline derivatives include inhibitory activity against EGFR-TK and antipsychotic activity. Futhermore, quinoline scaffolds are present in various drug molecules, including the antimalarial drugs aablaquine, chloroquine, mefloquine and primaquine, and the antibacterial agents gatifloxacin, levofloxacin, and moxifloxacin.
- Quinoline Price
- if you have any question on quinoline price, we will give the professional answers to your short questions.
Column Infos
- Paltusotine
- Crinetics’ once-daily oral paltusotine achieved the primary and all secondary endpoints in the phase 3 PATHFNDR-2 study in acromegaly patients.
Acromegaly is a serious rare disease generally caused by a pituitary adenoma, a benign tumor in the pituitary that secretes growth hormone (GH). Excess GH secretion causes excess secretion of IGF-1 from the liver. Prolonged exposure to increased levels of IGF-1 and GH leads to progressive and serious systemic complications, often resulting in bone, joint, cardiovascular, metabolic, cerebrovascular, or respiratory disease.
Paltusotine is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist and is currently in investigational Phase 3 studies for acromegaly and a Phase 2 study for carcinoid syndrome.